BMJ 1998;316:1611 ( 23 May )

Letters

Preventing RhD haemolytic disease of the newborn

    Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis
    Services should be centralised for pregnancies affected by RhD haemolytic disease

Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis

The first 150 words of the full text of this article appear below.

EDITORIn his editorial van Dijk advocates routine antenatal prophylaxis with anti-D immunoglobulin of all pregnant women who are RhD negative and refers to the consensus conference at the Royal College of Physicians in Edinburgh in April 1997.¹ He states that two dose schedules were consideredtwo doses of 500 IU of anti-D immunoglobulin, one at 28 weeks' gestation and the other at 34 weeks, and one dose of 1000 IU given between 28 and 30 weeksboth options being equally effective. He implies that the second option reflects Bowman's practice in Canada.² Bowman's programme in fact uses a dose of 1500 IU given at 28 weeks; maternal anti-D immunoglobulin concentrations are then monitored and additional anti-D immunoglobulin is given at around 36 weeks to those women in whom passive anti-D immunoglobulin is no longer detectable.

In my presentation to the conference the second option considered was a single dose of 1500 IUnot 1000 IUof anti-D . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study

Kirstin Finning, Pete Martin, Joanna Summers, Edwin Massey, Geoff Poole, and Geoff Daniels
BMJ 2008 336: 816-818. [Abstract] [Full Text] [PDF]

Single dose of anti-D immunoglobulin for antenatal prophylaxis is smaller in the Netherlands than in the United Kingdom

Bob van Dijk
BMJ 1998 317: 1253. [Extract] [Full Text]

Preventing RhD haemolytic disease of the newborn

Bob van Dijk
BMJ 1997 315: 1480-1481. [Extract] [Full Text]

Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review

Charles R Whitfield, Alaeddin Raafat, and Stanislaw J Urbaniak
BMJ 1997 315: 1504-1505. [Extract] [Full Text]

This article has been cited by other articles:

• Costa-Font, J., Gil, J. (2009). Exploring the pathways of inequality in health, health care access and financing in decentralized Spain. Journal of European Social Policy 19: 446-458 [Abstract]  
• Finning, K., Martin, P., Summers, J., Massey, E., Poole, G., Daniels, G. (2008). Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 336: 816-818 [Abstract] [Full text]  
• Elstad, J. I., Dahl, E., Hofoss, D. (2006). Associations between relative income and mortality in Norway: a register-based study. Eur J Public Health 16: 640-644 [Abstract] [Full text]  
• Kleindorfer, D. O., Lindsell, C. J., Broderick, J. P., Flaherty, M. L., Woo, D., Ewing, I., Schmit, P., Moomaw, C., Alwell, K., Pancioli, A., Jauch, E., Khoury, J., Miller, R., Schneider, A., Kissela, B. M. (2006). Community Socioeconomic Status and Prehospital Times in Acute Stroke and Transient Ischemic Attack: Do Poorer Patients Have Longer Delays From 911 Call to the Emergency Department?. Stroke 37: 1508-1513 [Abstract] [Full text]  
• Kerr-Pontes, L. R. S., Montenegro, A. C. D., Barreto, M. L., Werneck, G. L., Feldmeier, H. (2004). Inequality and leprosy in Northeast Brazil: an ecological study. Int J Epidemiol 33: 262-269 [Abstract] [Full text]  
• van Dijk, B. (1998). Single dose of anti-D immunoglobulin for antenatal prophylaxis is smaller in the Netherlands than in the United Kingdom. BMJ 317: 1253a-1253 [Full text]  

Online poll

Find out more >>